Weight Loss Peptides Compared: Semaglutide vs Tirzepatide vs Retatrutide

Tirzepatide delivers approximately 20% weight loss compared to 14% with semaglutide, while the investigational triple agonist retatrutide shows up to 28.7% reduction in clinical trials. These GLP-1 receptor agonists and related peptides have transformed obesity treatment, but they differ significantly in mechanism, efficacy, and side effect profiles. This guide breaks down the clinical evidence to help you understand how these medications compare.

This content is for informational purposes only and is not medical advice. Consult a healthcare provider before using any peptides.

How Do Weight Loss Peptides Work?

GLP-1 (glucagon-like peptide-1) receptor agonists work through multiple pathways to reduce body weight. According to research from the Cleveland Clinic, these peptides mimic naturally occurring gut hormones that regulate appetite and metabolism.

Central (brain) mechanisms:

• GLP-1 receptors in the hypothalamus regulate food intake
• The medications strengthen natural "stop eating" signals
• Preclinical studies show brain-restricted GLP-1 action alone reduces food intake

Peripheral (body) mechanisms:

• Slowed gastric emptying increases feelings of fullness
• Enhanced insulin secretion improves glucose control
• Reduced glucagon release prevents blood sugar spikes
• Decreased triglycerides and LDL cholesterol

The key distinction between these peptides lies in how many hormone receptors they target:

What Is Semaglutide (Wegovy/Ozempic)?

Semaglutide is a GLP-1 receptor agonist available as both an injection (Wegovy, Ozempic) and—as of December 2025—an FDA-approved oral pill. It was the first modern incretin therapy to achieve widespread use for weight management.

FDA-approved indications:

• Chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related conditions
• Reduction of cardiovascular death, heart attack, and stroke risk in adults with cardiovascular disease and obesity

Clinical trial results:

• STEP 1 trial: 15% mean weight loss over 68 weeks with semaglutide 2.4 mg weekly
• Oral Wegovy: 13.6% weight loss over approximately 15 months (comparable to injectable)

Dosing:

• Injectable: Up to 2.4 mg weekly (Wegovy) or 2.0 mg (Ozempic for diabetes)
• Oral: 25 mg once daily (launched January 2026)

Semaglutide has the most extensive real-world data and the longest track record among current weight loss peptides.

What Is Tirzepatide (Zepbound/Mounjaro)?

Tirzepatide is a dual GIP/GLP-1 receptor agonist manufactured by Eli Lilly. By targeting two incretin pathways instead of one, it produces greater weight loss than single-agonist GLP-1 medications.

FDA-approved indications:

• Chronic weight management (Zepbound)
• Type 2 diabetes (Mounjaro)
• Moderate-to-severe obstructive sleep apnea in adults with obesity

Clinical trial results (SURMOUNT program):

• SURMOUNT-1: 15–21% mean weight loss at 72 weeks depending on dose
• SURMOUNT-5 (head-to-head comparison): 20.2% weight loss with tirzepatide vs 13.7% with semaglutide at 72 weeks

Dosing:

• 5 mg, 10 mg, or 15 mg weekly (injectable only as of 2026)

According to research published in the New England Journal of Medicine, tirzepatide demonstrates superiority over semaglutide for both weight reduction and waist circumference decrease.

What Is Retatrutide?

Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. It is currently in Phase 3 clinical trials and has not yet received FDA approval.

Current status: Investigational (expected FDA decision: 2027)

Clinical trial results:

• Phase 3 TRIUMPH-4 (December 2025): 28.7% weight loss at the highest dose (12 mg) over 72 weeks
• Phase 2: 24.2% weight loss at 48 weeks
• Liver fat reduction: Up to 82.4% decrease in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)

Proposed dosing (investigational):

• 9 mg or 12 mg weekly

The addition of glucagon receptor activation appears to increase fat burning and energy expenditure beyond what dual agonists achieve.

Head-to-Head Comparison: Which Peptide Works Best?

Weight Loss Efficacy

The SURMOUNT-5 trial provides the most direct comparison between semaglutide and tirzepatide:

A meta-analysis published in PMC found tirzepatide produces approximately 4.2 kg more weight loss than semaglutide, with the effect being dose-dependent.

Cross-trial comparisons (not direct head-to-head) suggest retatrutide may achieve even greater weight loss:

Mechanism Differences

The escalating efficacy correlates with the number of receptor targets:

Semaglutide (GLP-1 only):

• Reduces appetite through brain signaling
• Slows gastric emptying
• Improves insulin secretion

Tirzepatide (GLP-1 + GIP):

• All GLP-1 effects, plus:
• GIP enhances insulin sensitivity
• GIP may improve fat oxidation
• Synergistic appetite suppression

Retatrutide (GLP-1 + GIP + Glucagon):

• All dual agonist effects, plus:
• Glucagon increases energy expenditure
• Glucagon promotes liver fat reduction
• Enhanced thermogenesis

Safety and Side Effects Comparison

Gastrointestinal Effects

According to a systematic review in ScienceDirect, both medications share similar gastrointestinal side effect profiles:

Common GI side effects (both medications):

• Nausea
• Diarrhea
• Constipation
• Vomiting
• Abdominal pain

Key differences:

• 79.8% of tirzepatide participants experienced GI events (vs 25% placebo)
• Semaglutide shows higher rates of vomiting, constipation, and GERD
• Semaglutide carries a 2.5x increased risk of gallbladder disorders (cholelithiasis)
• Tirzepatide did not show significant risk for biliary events

Serious Safety Considerations

Both medications carry FDA Boxed Warnings for potential thyroid tumor risk observed in animal studies.

Neither medication showed:

• Significant pancreatitis risk increase
• Substantial hepatic disorder increase

Discontinuation rates due to adverse events:

• Retatrutide: 12.2% (9 mg) to 18.2% (12 mg)
• Both semaglutide and tirzepatide show similar tolerability overall

Most side effects occur during the dose escalation phase and improve as the body adjusts.

Muscle Mass Concerns: What the Evidence Shows

A significant consideration with all weight loss peptides is the loss of lean body mass alongside fat.

The challenge:

• Research shows lean tissue loss comprises 26–40% of total weight lost
• Semaglutide: Up to 40% of weight loss may be lean mass
• This raises sarcopenia concerns, particularly in older adults

Mitigating strategies (from clinical case studies):

• Resistance training 3–5 days per week
• Protein intake of 0.7–1.7 g/kg/day
• Target 25–30 grams of protein per meal

Encouraging findings:

• Handgrip strength appears preserved despite lean mass reduction
• Bimagrumab combination trials show muscle preservation or even gain is possible
• Structured exercise protocols can result in lean mass changes ranging from -6.9% to +5.8%

What Happens When You Stop Taking These Medications?

Weight regain after discontinuation is a critical consideration. According to research published in eClinicalMedicine:

Regain statistics:

• 60% of lost weight regained at 1 year post-cessation
• Up to 75% regained when extrapolated beyond 52 weeks
• STEP 1 extension: Two-thirds of weight regained within 1 year of stopping semaglutide
• SURMOUNT-4: 14% weight regain after switching from tirzepatide to placebo

Why regain occurs:

• Hormonal compensation (increased ghrelin, decreased leptin)
• Return of "food noise" and cravings
• Metabolic adaptations persist

Mitigation strategies being studied:

• Gradual dose reduction to minimum maintenance dose
• Switching to every-other-week dosing (maintains ~75% of loss)
• Transition to older anti-obesity medications (metformin, topiramate, bupropion)
• Emphasis on concurrent lifestyle modification

Currently, GLP-1 agonists are considered long-term therapy, and clinical guidelines for discontinuation without rebound are still developing.

Cost and Accessibility (2026)

FDA-Approved Options

Generic Availability

As of August 2025, generic liraglutide (Saxenda) became available—the first generic GLP-1 for weight loss.

Upcoming Options

CagriSema (semaglutide + cagrilintide):

• Combines GLP-1 with long-acting amylin analog
• REDEFINE 1 trial: 20.4% weight loss at 68 weeks
• 60% of participants achieved ≥20% weight loss
• FDA filing submitted December 2025; decision expected late 2026

Orforglipron:

• Non-peptide oral GLP-1 (can be taken with food)
• Currently in Phase 3 trials

Who Should Consider Each Option?

Semaglutide may be appropriate for:

• Those who prefer an oral option (new pill form)
• Patients with cardiovascular disease (proven CV risk reduction)
• Those seeking the most established safety data
• First-line therapy for moderate weight loss goals

Tirzepatide may be appropriate for:

• Those targeting >15% weight loss
• Patients with concurrent type 2 diabetes
• Those with obstructive sleep apnea
• When semaglutide proves insufficient

Retatrutide (when approved) may be appropriate for:

• Treatment-resistant obesity
• Significant liver fat concerns (MASLD/MASH)
• Those requiring maximum weight loss intervention

All decisions should be made with a healthcare provider who can assess individual medical history, contraindications, and treatment goals.

Key Takeaways

• Tirzepatide produces ~6.5 percentage points more weight loss than semaglutide in direct head-to-head trials
• Retatrutide shows the highest efficacy (up to 28.7%) but remains investigational with expected 2027 approval
• GI side effects are common with all options but typically improve during treatment and are manageable
• Weight regain is significant (60–75%) after discontinuation—long-term use is typically recommended
• Muscle preservation requires intentional effort through resistance training and adequate protein intake
• Oral semaglutide (Wegovy pill) became the first oral GLP-1 approved for weight loss in December 2025

Frequently Asked Questions

Which weight loss peptide is most effective?

Based on clinical trials, retatrutide shows the highest weight loss (up to 28.7%) followed by tirzepatide (up to 21%) and semaglutide (up to 15%). However, retatrutide is not yet FDA-approved. Among approved options, tirzepatide demonstrates superior efficacy to semaglutide in head-to-head trials.

Can I take a pill instead of injections?

Yes, as of January 2026. The FDA approved oral semaglutide (Wegovy pill) in December 2025. Clinical trials showed 13.6% weight loss—similar to the injectable version. Other oral GLP-1 medications like orforglipron are in development.

What are the main side effects of weight loss peptides?

The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, and abdominal pain. These typically occur during dose escalation and improve over time. Semaglutide has a higher association with gallbladder issues, while all medications carry warnings about potential thyroid tumor risk.

Will I regain weight if I stop taking these medications?

Research indicates that approximately 60% of lost weight is regained within one year of stopping GLP-1 medications. Strategies being studied to minimize regain include gradual dose tapering, maintenance dosing schedules, and transitioning to other medications while emphasizing lifestyle modifications.

How do I preserve muscle while losing weight on these medications?

Clinical case studies suggest combining resistance training 3–5 days per week with protein intake of 25–30 grams per meal (0.7–1.7 g/kg/day total). While lean mass loss of 26–40% is typical, structured exercise protocols have achieved outcomes ranging from 6.9% lean mass loss to 5.8% gain.

Conclusion

The weight loss peptide landscape continues to evolve rapidly, with tirzepatide currently offering the most potent FDA-approved option and retatrutide poised to raise the bar further upon approval. While all three peptides work through GLP-1 pathways, the addition of GIP and glucagon receptor activity correlates with progressively greater weight loss.

Choosing between these medications requires weighing efficacy against individual health factors, cost, accessibility, and tolerance of side effects. The emergence of oral formulations and combination therapies like CagriSema suggests even more options are on the horizon.

For personalized guidance, consult with a healthcare provider who can evaluate your specific situation, medical history, and weight management goals.

---

This article was last updated in May 2026 and reflects the most current clinical trial data and FDA approvals available at publication.

Sources

• New England Journal of Medicine: Tirzepatide vs Semaglutide for Obesity (SURMOUNT-5)
• PMC: Comparative Efficacy Meta-Analysis
• Eli Lilly: Retatrutide Phase 3 Results
• Cleveland Clinic: GLP-1 Agonists
• ScienceDirect: Safety Comparison
• eClinicalMedicine: Weight Regain Meta-Analysis
• FDA: Oral Wegovy Approval
• New England Journal of Medicine: CagriSema REDEFINE 1
• PMC: Muscle Preservation Strategies
• American Diabetes Association: Muscle-Preserving Therapies